Compare Abeona Therapeutics Inc (ABEO) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Ascendis Pharma A/S — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Ascendis Pharma A/S trades at $274.69 (market cap $17.51B). The key difference: Ascendis Pharma A/S is far larger — about 46.9× Abeona Therapeutics Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | ASND | |
|---|---|---|
Market Cap | $373.32M | $17.51B |
Sector | Health | Health |
52-Week High | $7.23 | $274.50 |
52-Week Low | $4.17 | $163.32 |
Enterprise Value | $228.22M | $17.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Ascendis Pharma (ASND) trades at $266.97, down 2.74% on the day. The stock maintains a bullish technical outlook with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, revenue growth is strong, reaching $720.13M in 2025, but the company remains unprofitable with a net loss of $228.03M. Recent positive clinical trial data for TransCon CNP and inclusion in Russell indexes highlight ongoing business momentum.
The outlook is optimistic, driven by analyst consensus and a $320 price target, but risks include persistent losses, high debt levels, and reliance on pipeline success. Near-term performance hinges on Q2 2026 earnings versus the $1.29 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
